Early and often: reimagining patient community engagement to improve clinical trials feasibility

Parexel is proud to have collaborated with Global Genes on the whitepaper  “Early and Often: Reimagining Patient Community Engagement to Improve Clinical Trials Feasibility”. In this report, you'll discover compelling findings that emphasize the critical importance of engaging patient advocacy organizations early and often to accelerate trial success while reducing costs and eliminating barriers.

This comprehensive white paper underscores how involving patient communities from the outset of clinical trial design can fundamentally transform trial outcomes. In this report, you'll discover compelling findings that emphasize the critical importance of engaging patient advocacy organizations early and often. 

By adopting a patient-centric strategy, companies can accelerate trial success while reducing costs and eliminating barriers. This is more than a report—it’s a call to action for the biopharmaceutical industry to rethink its approach to rare disease clinical trials.
 

Read the whitepaper

Return to Insights Center